Search

SÖDERTÄLJE, Sweden, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Anocca AB, a leading T cell receptor-engineered T cell (TCR-T) cellular therapeutics company, announces it will present its novel platform approach to [...]

- Data show that Vaxart's HPV vaccine constructs stimulate specific T cell immune responses, reduce tumor size, and increase survival in an animal model of human papillomavirus (HPV)-related tumorigenesis - [...]

The development of VTP-300 in chronic Hepatitis B (CHB) and VTP-1000 in celiac disease will be prioritized. The pipeline prioritization is expected to result in a reduction in workforce of [...]

WARREN, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=sPboWaZGlNhMm47RHUPHLyGLciNcb1ubDxA3h_OxyP2YovoDcM15bNRcHpLgjAM2TAXNnz4pi9VE93m1At5dRleGkN1-Nn9PizeD6-qStsA= ('Tevogen' or 'Tevogen Bio') (Nasdaq: https://www.globenewswire.com/Tracker?data=nohkfL5cRHoJ7rW9WwTXbpKAw96I3oBMzpXdfTLQ93scPMvCDhT9OeR2Ew-8bDVVjV88nTSuL0-nGZFTbez0rkAIgYBAgsz9V3gLUZNizQw=), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, [...]

Successful completion of TVGN 489's proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities. Tevogen Bio plans to continue using its [...]

Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and Enhance Therapeutic Outcome in High-Risk Breast Cancer Boca Raton, Florida, April 08, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=GCytWNTcYVaSYNhadgCBTNreZuO9eKl_xHmpkRZtYqs82e-3IMHpteVkDi_kxvMML5XoFqAEa92C5-mYrJW2x2ZOICsoNSw4Uztj9oIi_xQ= (NASDAQ: [...]

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=IDdX0z9JQGZx3HOUtqyOT3XpcDerlj_kx6ZQnyxaGEJ6U5VDkeuwDSU0M7ZvgWE_dfUjUIeTCbp3kyVNePBL47f5wnVa28cqKHWblIXD-2Q= -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies [...]

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=y7jCuoRZow1lmDS8Y3Lzgkol9Q6UOcQYqjjc0VdgDwTNtscfsVCD7Gpucj1zPNf9wKRhj2ZHTeDSzE4drBNv8LxJS_oPFq0-Ydu-y3E1Mrk= - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced [...]

Murine Study by the Wistar Institute Builds Upon Favorable Results Previously Reported by IMUNON With its Prototype PlaCCine Vaccine Modality LAWRENCEVILLE, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=8BXXZiIhJHxyPmhzbbvSucSZIzYZO5xS6wuRoiTztvrP1r2mRzvqwnxjyNtngiR5nJh7cbd-Qu760Mmzow8eUA== (NASDAQ: [...]

AMTAGVI is the first FDA-approved T cell therapy for a solid tumor cancer and first treatment option for advanced melanoma after anti-PD-1 and targeted therapy AMTAGVI deploys patient-specific immune cells [...]

Results Demonstrate Potential Protective Immunity Against Multiple SARS-CoV-2 Variants ATLANTA, GA, Feb. 06, 2024 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=KBXurNQ-niuCQsXr2ELsBJpc9Uey6NVFr7fB_Y85guPNfanoDMErXqRd_BOLExcorlPZ2n62pnNg-MXkwWS19T3-h-4UTwBBNbAhNSu4KIY= - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies [...]

ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- https://www.globenewswire.com/Tracker?data=Nd9kPSqUyERyskI0nGnAL-X9gcfsLzRQHDBueMC0ndj2qH8g_OdWW-bDiZAdb9YmQe5G4gstdWxLTrtvddej_Q==, (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development [...]

Emergex has entered into an agreement with DEKA Research & Development ('DEKA') to assess the compatibility of Emergex's T cell-priming set-point immunotherapeutic candidates with DEKA's Intradermal Therapeutic Applicator. The collaboration [...]

Data showed ELI-002 administered as a monotherapy induced robust, polyfunctional and durable KRAS specific CD4+ and CD8+ T cell responses Tumor biomarker reduction was observed in 84% of patients correlating [...]

ABINGDON, United Kingdom, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Emergex Vaccines Holding Limited ('Emergex'), a clinical-stage biotechnology company addressing major global infectious diseases through the development of 100% synthetic T [...]

The combination of imdusiran and VTP-300 provides a meaningful reduction of HBsAg levels that are maintained well below baseline Preliminary data in subset of patients given imdusiran and then VTP-300 [...]

-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in Hard-to-Treat T-ALL/LBL Patients -- Results from [...]

HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting A Gilead-led Phase 1 clinical trial [...]

Replay a nnounces p artnership between product company Syena and JURA Bio to a dvance T c ell r eceptor NK t herapies in c ancer Collaboration leverages JURA Bio's [...]

Data Published From Phase 2 Open-Label Study of GEO-CM04S1 ATLANTA, GA, Sept. 19, 2023 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=zq9iv2b8JTxHfiKUIxDuYoKgJhZ-9NjucJD0079KFaTBrcbJ8eiOSQRchsv9cypqoSFvdWQGHusWUd9s17-xzsnGalO_3WLPry-5id676vQ= - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human [...]

Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=HS7JuYYU66mIcen2COI6Ko1FAjmYMkuTOi_iPQhai1XzDNEh0rcRZAX6iZxRAGAYW8NEkmxPgLnLPopgpx6taDm3T7nneNKdv6iHty2PxZ8= -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies [...]

Multi-center trial of novel autologous cell therapy APN401 leveraging two GMP-compliant manufacturing sites has received regulatory approval and patient recruitment has started; invIOs awarded up to 45% funding of trial [...]

BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, 'Elicio Therapeutics' or 'Elicio'), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of [...]

LGR5 is expressed, both in vitro and in vivo, by numerous human cancers, including colorectal, ovarian, gastric, brain, and pancreatic cancer. LGR5-targeting CAR-T cells effectively kill LGR5-expressing cancer cells in [...]

ATLANTA, GA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Seeking Improved Immune Response vs mRNA Vaccine Full Patient Enrollment Expected Within Six Months via https://www.globenewswire.com/Tracker?data=jYiQBtIv4JomrJxon7FMFbq6krTCqEiiDqXtQvUgE-fu7Tootk3JVFfkP6Uqc_N7OjD5dCHsg9m-uk7i4U4N0l1-YBPxztti1tai_NCOc0g= -- GeoVax Labs, Inc. (Nasdaq: GOVX), [...]

Seeking Improved Immune Response vs mRNA Vaccine ATLANTA, GA, July 20, 2023 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=Jb7KKiKP03ljeU6rNXDHOy2yBhcpbF2IAHODPAbCByb3Qx_uimiqEBC6xxWug6ik_Au47vD9l0yEUigFdk3YfAe_sKkOo5eJhqf0bj74dlA= - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines [...]

naNO-DENGUE trial results demonstrate that DengueTcP is well-tolerated with no treatment-related serious adverse events Immunogenicity data shows peptide antigen-specific effector and memory CD8+ T cells were elicited Clinical proof-of-concept demonstration [...]

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndrome A high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearance [...]

SAN MATEO, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CARGO), a biotechnology company advancing a next generation of CAR T-cell therapies for cancer, today announced that management [...]

Collaboration Brings Together TScan's Proprietary Target Discovery Platform and Amgen's Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30 Million Upfront With Potential Development and Commercial Milestone Payments of [...]

MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levels No neurotoxicity or dose-limiting toxicities observed Two out of nine patients showed early response on [...]

Analysis of Open-Label Portion of Ongoing Phase 2 Trial of GEO-CM04S1 Presented at 23rd Annual World Vaccine Congress Atlanta, GA, April 06, 2023 (GLOBE NEWSWIRE) -- via https://www.globenewswire.com/Tracker?data=MLSZ63jwqRcUw0jzQaTWyr8B6GlGr9QdSnc4aFNkicEXnVU22AJEfsfCjAM0BPBqTIH-l2AvP7Oev1Np7qHk4LpuoCbYyZBelgdxgbw_EHU= GeoVax Labs, [...]

Preclinical data demonstrates that LGR5-targeting CAR-T therapy has high potential as an effective therapeutic for human colorectal cancer. LGR5-targeting CAR-T cells effectively kill LGR5-expressing cancer cells in in vitro assays. [...]

Collaboration with the laboratory of Dr. Michael Dustin elucidates the mechanism of action of Immuno-STATs in activating disease-specific T cells by mimicking the natural formation of immune synapses BOSTON, Feb. [...]

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million [...]

The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million [...]

Preclinical evidence shows that LGR5 targeted CAR-T cells are able to kill ovarian cancer cells and to reduce ovarian cancer tumor burden in animal models The data suggests that LGR5 [...]

AIM technology represents a scalable therapeutic platform that has the potential to create new, multi-antigen specific therapies for virally driven infectious diseases, cancers and autoimmune diseases GAITHERSBURG, Md., Jan. 18, [...]

Activity of STAT3 degrader in preclinical model of cutaneous T-cell lymphoma (CTCL) validates selective STAT3 degradation as a potential therapeutic strategy for STAT3-driven T cell malignancies Preclinical study highlights the [...]

VB10.NEO induced a T cell response in 95% of the patients, including expansion of both novel and pre-existing T cells The responses were broad, and the majority of the encoded [...]

PRESS RELEASE Emergex Confirms Synthesis of a CD8+ T cell Adaptive Vaccine for Smallpox and Monkeypox Vaccine construct comprised predominantly of peptides from early 'eclipse phase' antigens targeting infections before [...]

Professor Swanton joins Achilles SAB member Dr. Christopher Klebanoff and Dr. John Haanen on the key opinion leader panel to discuss neoantigens as valuable immunotherapy targets Virtual Roundtable to take [...]

Nykode's vaccine candidate boosted Spike-specific T cell responses and induced de novo T cell responses to non-Spike antigens found across SARS-CoV-2 variants Nykode's Vaccibody technology combined with immunogenic T cell [...]

LAWRENCEVILLE, N.J., Sep 01, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:CLSN), EQNX::TICKER_END PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused [...]

LONDON, Aug 05, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END As the pandemic crisis has entered a new phase, it is a common belief among the scientific community that [...]

HOUSTON, June 23, Jun 23, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END -- Regulatory T Cell (Treg)-derived exosome data have been published in the peer-reviewed journal Frontiers of Immunology [...]

LONDON, June 15, Jun 15, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END With over 460 million global cases thus far, 6 million of which have resulted in death, the [...]

WARMINSTER, Pa. and OXFORD, Jun 06, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NASDAQ:ABUS),(NasdaqGM:VACC), EQNX::TICKER_END Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA [...]

LONDON, May 26, May 26, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START EQNX::TICKER_END - First clinical data for NVG-111, a novel ROR1xCD3 bispecific antibody in patients with relapsed / refractory [...]

BOSTON, March 29, Mar 29, 2022 (GLOBE NEWSWIRE via COMTEX) -- -- ELI-005 administration safely promotes robust cellular and humoral immunity through potent and targeted engagement of the lymph nodes [...]